Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy  by Parving, Hans-Henrik et al.
Kidney International, VoL 49 (1996), pp. 1778 —1 782
Benefits of long-term antihypertensive treatment on prognosis in
diabetic nephropathy
HANS-HENRIK PARVING, PETER JACOBSEN, KASPER RossING, ULLA M. SMIDT, EVA HOMMEL,
and PETER RossING
Steno Diabetes Center, Gentofte, Denmark
Benefits of long-term antihypertensive treatment on prognosis in
diabetic nephropathy. We assessed the prognosis of diabetic nephropathy
during long-term antihypertensive treatment as compared to the prognosis
during the natural history of this complication in a prospective study of all
IDDM patients (N = 45) aged under 50 with onset of diabetes before the
age of 31 who developed diabetic nephropathy between 1974 and 1978 at
Steno Diabetes Center, and were followed until death or for at least 16
years [median 16 (4 to 21) years]. Antihypertensive treatment was started
3 (0 to 13) years after onset of diabetic nephropathy. Mean arterial blood
pressure at start of antihypertensive treatment was 148/96 (so 12/10) mm
Hg and 143/86 (16/6) mm Hg during the whole interval of antihypertensive
treatment (P < 0.01). The cumulative death rate was 45% (95% C.I. 38 to
52) 16 years after Onset of diabetic nephropathy, in contrast to previous
reports 88% and 94% 12 and 16 years after Onset of diabetic nephropathy,
respectively. The median survival time in our study exceeded 16 years as
compared to five and seven years in untreated patients in the past. Uremia
was the main cause of death (12 patients; 55%). In 1994 serum creatinine
was 116 (74 to 311) jsmol/liter in the 23 surviving patients. The preserva-
tion of kidney function and the prognosis of diabetic nephropathy has
improved during the past two decades mainly because of effective antihy-
pertensive treatment.
Between 25% and 40% of patients with insulin-dependent
diabetes mellitus (IDDM) develop diabetic nephropathy [1—41.
Diabetic nephropathy is a leading cause of end-stage renal disease
in the Western world and the cost of caring for these patients
alone currently exceeds $2 billion in the U.S., and the amount is
still rising [5]. IDDM patients suffering from diabetic nephropathy
have an increased morbidity and mortality due to an excess of
cardiovascular events and particularly due to the development of
end-stage renal failure [6]. The median survival time after onset of
persistent proteinuria has previously been reported as 5 to 10
years in epidemiological studies of the natural histoiy of diabetic
nephropathy [1, 2, 7].
Several studies dealing with small numbers of patients have
shown that effective antihypertensive treatment with conventional
drugs and angiotensin converting enzyme (ACE) inhibitors post-
pones renal insufficiency in IDDM patients with diabetic nephrop-
athy [8—14]. Recently, a large multicenter study lasting 2.7 years
has confirmed and extended this finding by the demonstration of
a more beneficial effect of ACE inhibitors versus non-ACE
inhibitors on improving kidney function, delaying death and
© 1996 by the International Society of Nephrology
dialysis/transplantation in IDDM patients with moderately ad-
vanced diabetic nephropathy [15].
To elucidate the long-term effect of conventional antihyperten-
sive treatment on the prognosis in diabetic nephropathy we
prospectively studied an incidence cohort of 45 IDDM patients
with onset of diabetic nephropathy between 1974 and 1978,
following them until death or for at least 16 years. An interim
report of this study was published in 1989 [16].
Methods
Patients
All IDDM patients with onset of diabetes before the age of 31
who were referred with proteinuria or who developed persistent
proteinuria between 1974 and 1978 at the Steno Diabetes Center
were identified by one of us (H-H.P.) as described previously [16].
Owing to the time lag between onset of proteinuria and fully
developed persistent proteinuria this identification took place
between 1976 and 1980. We studied 45 patients suffering from
diabetic nephropathy [9] and fulfilling the following inclusion
criteria: onset of diabetes before the age of 31, current age below
50 at onset of persistent proteinuria (> 0.5 g/24 hr on at least 4
consecutive visits to the outpatient clinic), and onset of persistent
proteinuria between 1974 and 1978. All patients had been depen-
dent on insulin from the time of diagnosis, and all received at least
two daily injections of highly purified porcine insulin during the
1970s increasing to two to four daily injections during the 1980s.
They had a normal diabetic diet containing 45 to 55% carbohy-
drate, 30 to 35% fat and 15 to 20% protein throughout the study,
and none of the patients had their intake of salt or protein
restricted.
Of the 45 patients, twenty were women. At onset of persistent
proteinuria mean (SD) age and diabetes duration were 30 (7) and
18 (7) years, respectively. Thirty-seven patients had onset of
diabetes before the age of 21. The annual number of patients
developing persistent proteinuria ranged from 7 to 11 during the
enrollment period.
At onset of proteinuria 3 patients had no retinopathy, 14 had
background and 28 proliferative retinopathy. Biopsy specimens
were taken from the kidneys of the three patients who lacked
retinopathy and suffered from diabetes for less than ten years.
Diffuse diabetic glomerulosclerosis was found in all three.
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Fig. 1. Arterial blood pressure during conventional antihypertensive treat- 0 2 4 6 8 10 12 14 16
ment in IDDM patients with diabetic nephropathy. Vertical bars represent
SE. Prior to treatment mean (SD) systolic and diastolic pressures were 148 Duration of nephropathy years
12] and 96 [101, respectively. Fig. 2. Cumulative death rate during the natural histoiy of diabetic nephrop-
athy in JDDM patients. (x, N = 45, Knowles [71; , N = 360, Andersen et
al [1]; •, N 67, Krolewski et a! [21) compared with patients who had
effective antihypertensive treatment (0, N 45, present study).
Methods
The patients visited the clinic every two to four months during
the whole follow-up period, which lasted a median time of 16 a median time interval from onset of proteinuria to start of
years (range 4 to 21 years). treatment of three (0 to 13) years. Two patients received no
Blood pressure was measured with a standard clinical sphyg- treatment since they remained normotensive during the whole
momanometer (cuff 25 >< 12 cm) on the right arm, the patients study interval. Seven patients received monotherapy with a di-
having been supine or sitting for at least 10 minutes. The diastolic uretic (furosemide or bendrofluazide), 16 received diuretics to-
blood pressure was taken as the point at which the Korotkoff gether with metoprolol (N = 10) or captopril (N = 2) or
sounds disappear (phase V). For each patient a mean systolic and methyldopa (N = 2) or nifedipine (N = 2) and 20 patients
diastolic blood pressure was calculated for each year. received three or more types of antihypertensives (14 received
Antihypertensive treatment was started if at least three consec- diuretics, metoprolol, and hydralazine, 2 received diuretics, meto-
utive measurements showed a diastolic blood pressure  95 mm prolol, and nifedipine, 1 received diuretics, metoprolol, and
Hg (N = 29) or if the patient had edema and a sustained diastolic methyldopa, and 3 received diuretics, metoprolol, captopril, and
blood pressure of  90 mm Hg (N = 14). The aim of antihyper- hydralazine).
tensive treatment was a stable reduction in diastolic blood pres- The average course of arterial blood pressure is shown in
sure to less than 90 mm Hg. Figure 1. In the 43 patients receiving antihypertensive treatment
Serum creatinine concentration was measured by a reaction mean blood pressure at start of antihypertensive treatment was
rate kinetic technique eliminating pseudo-creatinines [17]. 148/96 (12/10) mm Hg, whereas the average blood pressure during
Hemoglobin A1 was measured by high performance liquid the whole treatment interval was kept significantly lower 143/86
chromatography (Bio-Rad-Diamat, Richmond, CA, USA; normal (16/6) mm Hg (P < 0.01). Thirty-four patients (79%) on antihy-
range 4.3 to 6.2%) and by isoelectric focusing methods (normal pertensive treatment had a mean diastolic blood pressure below
range 4.1 to 6.1%). 90 mm Hg during the follow-up period.
.Statistics
The cumulative death rate was 45% (95% C.! 38 to 52) 16 years
after onset of diabetic nephropathy (Fig. 2). Two patients with
Data are expressed as mean (SD) unless otherwise stated. renal death (dialysis/transplantation) were included in the data on
Confidence intervals for the 16 year death rate were calculated at death to make our results comparable with older studies dealing
the 95% level by the exact binomial method. The cumulative with the natural history of diabetic nephropathy (pre-dialysis/
incidence of end-stage renal disease and doubling of serum transplantation era). The overall mortality in 1994 was 49% with
creatinine was calculated for one year intervals with a life table uremia (serum creatinine concentration > 500 mol/liter at time
method that took into account differences in the intervals of of death) as the main cause of death (12 patients; 55%) followed
follow-up (95% confidence intervals). Arterial blood pressure by cardiovascular causes (Table 1). Causes of death were deter-
before and during antihypertensive treatment was compared using mined from hospital records and death certificates.
paired Student's 1-test. All calculations were performed using The cumulative incidence of end-stage renal disease was 31%
SPSS version 6.0 (SPSS Inc., Chicago, IL, USA). (95% C.I. 23 to 39) 16 years after onset of diabetic nephropathy
Results
(Fig. 3) as compared to 73% in the study of Krolewski et al [2]
observing the natural history of diabetic nephropathy (without
The median follow up was 16 years. The follow-up was incom- antihypertensive treatment). In our study thirteen patients (29%)
plete regarding blood pressure and serum creatinine in four had developed end-stage renal disease in 1994.
patients who left the clinic after 10, 15, 16 and 17 years of The cumulative incidence of doubling in serum creatinine
follow-up. One of these patients later died from uremia, while the (> 177 jsmol/liter) 16 years after onset of nephropathy was 44%
remaining three patients were still alive in 1994. (95% C.!. 27 to 16; Fig. 4), In 1994 seventeen patients had
Antihypcrtensive treatment was given to 43 (96%) patients with doubled their level of serum creatinine.
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Table 1. Causes of death in IDDM patients with diabetic nephropathy
Years of follow-up
16 >16 0—20
Uremia 11 1 12
Myocardial infarction 3 3
Intestinal arterial occlusion 1 1
Stroke 1 1 2
Pulmonary embolism 1 1
Ketoacidosis 1 1
Sudden death 2 2
Total 20 2 22
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Fig. 4. Cumulative incidence of doubling of baseline serum-creatinine (to a
value > 177 p.mol/liter) in 45 JDDM patients with diabetic nephropathy
treated with antihypertensive therapy.
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Fig. 3. Cumulative incidence of end-stage renal disease (defined by
Krolewski et al 12] as uremia or death due to non-renal disease with a serum
creatinine > 221 pmol/liter) in JDDM patients with diabetic nephropathy.
Symbols are: •, N = 67, Krolewski et al [21; 0, N = 45, present study.
In 1994 serum creatinine was 116 (74 to 311) imol/Iiter in the
23 surviving patients with only 5 patients having a serum creati-
nine above 150 .tmol/1iter (Fig. 5).
The average hemoglobin A1 from 1984 to 1994 was 9.1% (1.1).
Discussion
Our prospective study of an incidence cohort of Caucasian
IDDM patients suffering from diabetic nephropathy treated with
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Fig. 5. Serum-creatinine concentration related to death in 45 JDDM patients
with diabetic nephropathy. Twelve patients with uremia (2 with renal death
(dialysis/transplantation)) (•), six patients died of cardiovascular causes(A), and four of other causes (s). Twenty-three patients survived (+) at
end of study.
conventional antihypertensive treatment revealed a cumulative
death rate of 45% 16 years after onset of persistent proteinuria in
contrast to previous reports of 88%, 73%, and 94% 12 and 16
years, respectively, after onset of diabetic nephropathy and no
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Table 2. Prognosis in IDDM patients with diabetic nephropathy
Cumulative death rate
% With onset of Age at onset of Median year of (%) after 16 years
NC). of % Of diabetes before diabetes onset of diabetes with proteinuria 95%
patients women age 21 range range confidence interval
Knowles (1971) 45 48 100 9 (0—16) 1952 88'
Andersen et al (1983)
Krolewski et al (1985)
360
67
37
46
70
100
14(0—30)
12 (0—20)
(1930—1962)
(1923—1952)
1959
94
73b
Present study 45 44 82 12 (1—32) 1959
(1937—1971)
45 (38—52)
Cumulative death rate (%) after 12 years
b Only death due to end stage renal failure or due to non-renal disease with serum creatinine >2.5 mgldl (>221 jsmol/liter) taken into account
treatment of hypertension (Table 2) [1, 2, 71. The 73% number is
a minimum value, as Krolewski et al [2] included only death due
to ESRD. The median survival time in our study exceeded 16
years as compared to five and seven years in the prior studies [1,
7]. A significant reduction in the diastolic blood pressure occurred
during the treatment period and 79% of the patients reached our
treatment goal, a stable reduction in diastolic blood pressure to
less than 90 mm Hg. Uremia was the main cause of death as in the
three earlier studies describing the natural history of diabetic
nephropathy in IDDM patients. Among the surviving 23 patients
in our study only five had a serum creatinine concentration > 150
iimol/liter in 1994, suggesting a low risk of progression to ESRD
for the remaining patients.
All four investigations are comparable with respect to sex ratio,
age at onset of diabetes, and criteria applied for the clinical
diagnosis of diabetic nephropathy. Unfortunately, blood pressure
of untreated patients was not reported. Apart from antihyperten-
sive treatment, the treatment modalities applied at the Steno
Diabetes Center were nearly the same in the former study by
Andersen et al [11 involving 360 IDDM patients and in the present
investigation. The potential impact of differences in the median
calendar year of diagnosis of diabetes on the prognosis can be
ruled out according to Krolewski et al [2]. Studies of the natural
course of glomerular filtration rate (GFR) support this conclusion
[18—20]. If, as suggested in these studies, the rate of decline in
GFR (about 12 mI/mm/year) is linear with time, then the median
survival time from onset of nephropathy can be estimated to be 8
to 11 years, depending on the initial GFR level. This estimate
agrees closely with a cumulative incidence of ESRD of 50% ten
years after onset of persistent proteinuria as demonstrated by
Krolewski et al (Fig. 3) [2]. Even though the above-mentioned
findings indicate that patients in the present study are comparable
with patients in the previous studies, apart from the antihyperten-
sive medication, a change in the natural course of diabetic
nephropathy with time cannot be ruled out.
All our patients had a normal diabetic diet without salt or
protein restriction. Our patients received conventional insulin
treatment with at least two daily injections of insulin, and their
average hemoglobin A1 concentration was 9.1%. None of our
patients received lipid lowering drugs, and 50% of the patients
smoked. Our findings make it highly unlikely that the improve-
ment in prognosis in diabetic nephropathy during the past two
decades is due to modifications in well established non-hemody-
namic progression promoters such as: protein intake, glycemic
control, hypercholesterolemia and smoking [20—25]. This conten-
tion is supported by Mathiesen et al [26], who showed that the
survival of IDDM patients with nephropathy has improved sub-
stantially since the early use of effective antihypertensive treat-
ment with conventional drugs has become routine in their clinic.
Recently the Collaborative Study Group of Angiotensin Convert-
ing Enzyme Inhibition with Captopril in Diabetic Nephropathy
[15] demonstrated a risk reduction of 56% (95% CI, 26 to 80%,
P = 0.002) in the 102 patients with serum creatinine levels greater
than 133 .tmol/liter, and a risk reduction of 46% (95% CI, —22 to
76%, P = 0.14) in 307 patients with serum creatinine < 133
imol/liter, for occurrence of death or progression to dialysis or
transplantation in IDDM patients treated with captopril versus
placebo. All hypertensive patients (N = 308) in this trial received
conventional antihypertensive treatment plus captopril or placebo
therapy. The reduction in risk of the primary study end point, that
is, time to doubling of the baseline serum creatinine concentration
to at least 177 amol/liter, was 68% (95% CI, 39 to 83%, P <
0.001) in patients with serum creatinine above 133 jimol/liter at
baseline, and 33% (95% CI, —44 to 69%, P = 0.31) in the
subgroup of 307 patients with serum creatinine < 133 mol/liter
at baseline [15], Our study suggests that the disappointing results
obtained by Lewis et al [15] in the early stage of diabetic
nephropathy (serum creatinine level < 133 j.mol/liter) probably
can be explained by the insensitive technique for estimating
changes in kidney function and by the rather short duration of the
study, a median of 2.7 years. The cumulative incidence of doubling
of baseline serum creatinine was only 3% five years after onset of
diabetic nephropathy in our patients who all had normal serum
creatinine at enrollment in the study (Fig. 4). Thereafter the
cumulative incidence increases linearly at a rate of approximately
4% per year. Another shortcoming of the criterion, doubling of
creatinine, is the preferential detection of so-called "fast tracking
patients." Furthermore, our study demonstrates a low (5%)
cumulative incidence of ESRD six years after onset of diabetic
nephropathy (Fig. 3).
In conclusion, effective antihypertensive treatment, which post-
pones ESRD, is the most likely explanation of the improved
prognosis during the past two decades in IDDM patients with
diabetic nephropathy. It may also improve the prognosis by
reducing the excess cardiovascular mortality in diabetic nephrop-
athy.
Reprint requests to Hans-Henrik Parving, M.D., Steno Diabetes Center,
Niels Steensens J/ej 2, DK-2820 Gentofte, Denmark.
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